Results 131 to 140 of about 53,170 (302)

Drug Induced Acute Dystonia [PDF]

, 2009
Dystonia is a common neurological syndrome characterised by sustained muscle contractions that produce repetitive movements or abnormal postures. This disorder may be inherited or caused by other factors such as birth-related or other physical trauma ...
Sarma, Shanthi, Ng, B
core  

Molecular mechanisms in DYT-PRKRA: pathways regulated by PKR activator protein PACT

Dystonia
Dystonia-PRKRA (DYT-PRKRA), previously termed dystonia 16 (DYT16), is a movement disorder which currently has very limited treatments available and no cure.
Tricia A. Simon, Rekha C. Patel
doaj   +1 more source

Abrupt Reoccurrence of Acquired Postencephalitic Hemidystonia After Unexpected Discontinuation of Thalamic DBS: An Embarrassing Situation

Movement Disorders Clinical Practice, EarlyView.
Arif Abdulbaki, Joachim Runge, Assel Saryyeva, Joachim K. Krauss   +3 more
wiley   +1 more source

Movement Disorders in Developmental and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Monogenic developmental and epileptic encephalopathies (DEE) frequently feature co‐occurring movement disorders. Gene discovery has expanded epilepsy‐dyskinesia syndromes (EDS) from classic associations such as stereotypies in Rett syndrome to PRRT2‐related infantile seizures with paroxysmal dyskinesia and crouched gait in SCN1A ...
Shekeeb Mohammad, Darius Ebrahimi‐Fakhari, Hugo Morales‐Briceno   +2 more
wiley   +1 more source

Phenotypic Exploration in Patients with Heterozygous Variant in AFG3L2 Gene: A Case‐Series and Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Variants in AFG3‐Like Matrix AAA Peptidase, Subunit 2 (AFG3L2) gene are associated with diverse clinical phenotypes. Here, we describe phenotypic findings of two unrelated children with de novo heterozygous variant and one family with inherited heterozygous variant in AFG3L2 gene.
Sangeetha Yoganathan, Laura Tochen, Jacky Ganguly, Sayoni Roy Chowdhury, Haya S AlFaris, Vivek Pai, Andrea LeBlanc‐Millar, Sara Breitbart, Hrishikesh Kumar, Manohar Shroff, Arun Reginald, Grace Yoon, Alfonso Fasano, George M Ibrahim, Carolina Gorodetsky   +14 more
wiley   +1 more source

Tardive Dystonia: A review [PDF]

, 2009
Dystonia is a common neurological syndrome characterised by sustained muscle contractions that produce repetitive movements or abnormal postures. This disorder may be inherited or caused by other factors such as birth-related or other physical trauma ...
Sarma, Shanthi, Ng, B
core  

Perinatal Post‐Anoxic Spinal Cord Injury: A Barrier to Pallidal Neuromodulation? About 2 Cases

Movement Disorders Clinical Practice, EarlyView.
Marylou Grasso, Cassandra Coelho, Emilie Chan‐Seng, Philippe Coubes, Gaëtan Poulen   +4 more
wiley   +1 more source

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy, Frederique Leh, Alexandra Foubert‐Samier, Soizic Leguy Bonnet, Guillaume Baille, Margherita Fabbri, Margaux Dunoyer, Lise Mantisi, Caroline Giordana, Anaïs El Ouartassi, Olivier Rascol, Wassilios G. Meissner, David Bendetowicz, Marie Vanel, David Grabli, Fabienne Ory‐Magne, Sophie Drapier   +16 more
wiley   +1 more source

Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder

Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan, Haya S. AlFaris, Lindsey Vogt, Michele Eid, Anika Menetrey, Sayoni Roy Chowdhury, Dawn Codeiro, Pradeep Krishnan, Liali Aljouda, Emily W.Y. Tam, Carolina Gorodetsky   +10 more
wiley   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau, Pierre Karam, Anne Forestier, Bertrand Degos   +3 more
wiley   +1 more source